Literature DB >> 19959106

Optimising the conditioning regimen for acute myeloid leukaemia.

Frederick R Appelbaum1.   

Abstract

The conditioning regimen administered prior to allogeneic transplantation for acute myeloid leukaemia (AML) must be sufficiently immunosuppressive to ensure engraftment, and contributes to the anti-leukaemic impact of the procedure. A broad spectrum of regimens have been studied, varying in their intensity, whether high-dose or reduced intensity, and in the agents used, containing total body irradiation (TBI) plus cyclophosphamide, fludarabine, busulfan and/or anti-thymocyte globulin. Over the past 2 decades, research has influenced the way conditioning regimens are applied. Newer research shows that targeted radiotherapy using an anti-CD45 antibody should be able to reduce toxicity, improve tumour cell kill and thereby improve results.

Entities:  

Mesh:

Year:  2009        PMID: 19959106      PMCID: PMC3207636          DOI: 10.1016/j.beha.2009.10.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  22 in total

1.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.

Authors:  R A Clift; C D Buckner; F R Appelbaum; E Bryant; S I Bearman; F B Petersen; L D Fisher; C Anasetti; P Beatty; W I Bensinger
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

2.  Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.

Authors:  Martin Bornhauser; Barry Storer; John T Slattery; Frederick R Appelbaum; H Joachim Deeg; John Hansen; Paul J Martin; George B McDonald; W Garrett Nichols; Jerald Radich; Ann Woolfrey; Andreas Jenke; Eberhard Schleyer; Christian Thiede; Gerhard Ehninger; Claudio Anasetti
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

3.  Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse.

Authors:  D Blaise; D Maraninchi; E Archimbaud; J Reiffers; A Devergie; J P Jouet; N Milpied; M Attal; M Michallet; N Ifrah
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

4.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.

Authors:  R A Clift; C D Buckner; F R Appelbaum; S I Bearman; F B Petersen; L D Fisher; C Anasetti; P Beatty; W I Bensinger; K Doney
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

5.  Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation.

Authors:  E D Thomas; R A Clift; J Hersman; J E Sanders; P Stewart; C D Buckner; A Fefer; R McGuffin; J W Smith; R Storb
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-05       Impact factor: 7.038

6.  Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant.

Authors:  R Storb; C Yu; J M Zaucha; H J Deeg; G Georges; H P Kiem; R A Nash; P A McSweeney; J L Wagner
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

7.  Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.

Authors:  G Helenglass; R L Powles; T J McElwain; A Lakhani; S Milan; M Gore; A Nandi; A Zuiable; T Perren; G Forgeson
Journal:  Bone Marrow Transplant       Date:  1988-01       Impact factor: 5.483

8.  Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Authors:  J A Russell; H T Tran; D Quinlan; A Chaudhry; P Duggan; C Brown; D Stewart; J D Ruether; D Morris; S Glick; E Gyonyor; B S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

9.  Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.

Authors:  F R Appelbaum; P A Brown; B M Sandmaier; R Storb; D R Fisher; H M Shulman; T C Graham; F G Schuening; H J Deeg; J A Bianco
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

10.  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.

Authors:  O Ringdén; T Ruutu; M Remberger; J Nikoskelainen; L Volin; L Vindeløv; T Parkkali; S Lenhoff; B Sallerfors; P Ljungman
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

View more
  9 in total

1.  Adoptive T-cell therapy of melanoma using designer T-cell receptors.

Authors:  Kim Margolin
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

2.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

Review 3.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?

Authors:  Lazaros J Lekakis; Brenda W Cooper; Marcos G de Lima
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

4.  Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Authors:  Lynn Quek; Paul Ferguson; Marlen Metzner; Ikhlaaq Ahmed; Alison Kennedy; Catherine Garnett; Sally Jeffries; Claudia Walter; Kim Piechocki; Adele Timbs; Robert Danby; Manoj Raghavan; Andrew Peniket; Mike Griffiths; Andrew Bacon; Janice Ward; Keith Wheatley; Paresh Vyas; Charles Craddock
Journal:  Blood Adv       Date:  2016-12-14

5.  Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation.

Authors:  David S Wenger; Matthew Triplette; Kristina Crothers; Guang-Shing Cheng; Joshua A Hill; Filippo Milano; Shahida Shahrir; Gary Schoch; Lisa K Vande Vusse
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-09       Impact factor: 5.742

6.  Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.

Authors:  Xufeng Chen; Eric H Radany; Patty Wong; Shenglin Ma; Kan Wu; Bing Wang; Jeffrey Y C Wong
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

7.  Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.

Authors:  C Bradbury; A E Houlton; S Akiki; R Gregg; M Rindl; J Khan; J Ward; N Khan; M Griffiths; S Nagra; R Hills; A Burnett; N Russell; P Vyas; D Grimwade; C Craddock; S D Freeman
Journal:  Leukemia       Date:  2014-11-26       Impact factor: 11.528

8.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742

9.  Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.

Authors:  Sultan Altouri; Mitchell Sabloff; David Allan; Harry Atkins; Lothar Huebsch; Dawn Maze; Rajiv Samant; Christopher Bredeson
Journal:  Case Rep Hematol       Date:  2016-11-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.